Company Overview
Sera Prognostics, Inc., a women's health company, discovers, develops, and commercializes blood-based biomarker tests, and predictive analytic products and services in the United States. The company develops the PreTRM test, a non-invasive blood test given to a pregnant woman, carrying a single fetus, during weeks 18 through 20 of gestation. It is also involved in the development of a pipeline of novel blood-based biomarker tests and predictive analytic products and services for pregnancy related conditions, such as time-to-birth, predictive analytics product, pregnancy risk prediction panel, preeclampsia, and fetal growth restriction. The company was incorporated in 2008 and is headquartered in Salt Lake City, Utah.
Why Investors Should Care
Revenue has grown at a 34.2% CAGR over the past five years.
Carries low leverage with a debt-to-equity ratio of 0.05.
Recent Developments
- Dec 2025 Revenue of $81.00K (+5.2% YoY); net profit $-31.93M.
- Trailing 12 Months Year-on-year growth — revenue +76.5%.
- 5-Year Trend Long-term compounding — revenue CAGR 34.2%.
Growth & Price Performance
Compounded Sales Growth
| 5 Years: | 34.16% |
| 1 Year: | 76.50% |
Stock Price Performance
| 1 Year: | -12.61% |
| 6 Months: | +4.15% |
| 3 Months: | -4.29% |
| 1 Month: | -2.90% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMABelow
- Price vs 200-DMABelow
- RSI (14)47.34 · Neutral
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
- Compounding revenue at 34.2% over 5 years.
CONS
- Trading 46.4% below its 52-week high.
- In a downtrend (50-DMA below 200-DMA).
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | SERA Sera Prognostics, Inc. PHARMA | 2.01 | -3.05 | $77.35M | 0.00% | -46.95% | -45.03% | 34.16% | - |
| 2 | LLY Eli Lilly and Company SPXR3KPHARMA | 1,123.91 | 37.80 | $1.00T | 0.60% | - | 102.29% | 7.20% | 11.41% |
| 3 | JNJ Johnson & Johnson SPXR3KPHARMA | 269.12 | 31.22 | $648.55B | 1.98% | 14.88% | 25.74% | 2.43% | 4.76% |
| 4 | ABBV AbbVie Inc. SPXR3KPHARMA | 248.78 | 70.48 | $439.62B | 2.78% | 10.47% | -129.24% | 1.75% | -29.06% |
| 5 | MRK Merck & Co., Inc. SPXR3KPHARMA | 148.46 | 118.77 | $366.28B | 2.31% | - | 6.96% | 5.64% | 10.01% |
| 6 | UNH UnitedHealth Group Incorporated SPXR3KPHARMA | 400.84 | 25.74 | $359.79B | 2.47% | 9.74% | 14.15% | 10.40% | 5.43% |
| 7 | NVS Novartis AG PHARMA | 137.70 | 20.80 | $261.73B | 3.36% | 21.09% | 30.35% | 9.25% | 26.22% |
| 8 | AZN AstraZeneca PLC NDXPHARMA | 160.04 | 23.99 | $248.20B | 2.00% | 15.97% | 21.96% | 9.82% | 45.96% |
| 9 | TMO Thermo Fisher Scientific Inc. SPXR3KPHARMA | 603.02 | 32.49 | $222.97B | 0.29% | 8.14% | 13.51% | 8.81% | 12.95% |
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Mar 2020 | Jun 2020 | Sep 2020 | Mar 2021 | Jun 2021 | Sep 2021 | Mar 2022 | Jun 2022 | Sep 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | 6.00K | 5.00K | 13.00K | 20.00K | 23.00K | 38.00K | 78.00K | 87.00K | 100.00K | 123.00K | 42.00K | 0 | 24.00K | 29.00K | 38.00K | 17.00K | 16.00K | 10.00K | 14.00K |
| Cost of Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 40.00K | 41.00K | 41.00K | 42.00K | 42.00K |
| Gross Profit | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -2.00K | -24.00K | -25.00K | -32.00K | -28.00K |
| Operating Expenses | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 9.25M | 9.30M | 8.96M | 8.92M | 9.33M |
| Operating Income | - | -4.28M | -4.64M | -6.03M | -7.38M | -9.44M | -12.30M | -11.75M | -11.19M | -11.33M | -11.46M | -8.18M | -9.10M | -9.25M | -8.86M | -9.25M | -9.32M | -8.98M | -8.95M | -9.36M |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -7.97M | -7.81M | -7.57M | -7.64M | -8.20M |
| Interest Expense | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 4.00K | 2.00K | 2.00K | 1.00K | 2.00K |
| Pretax Income | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -8.19M | -8.05M | -7.81M | -7.88M | -8.40M |
| Tax Provision | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Net Income | -4.70M | -4.71M | -5.07M | -6.36M | -6.31M | -9.86M | -12.21M | -11.52M | -10.71M | -10.56M | -10.54M | -7.21M | -8.10M | -8.30M | -7.92M | -8.19M | -8.05M | -7.81M | -7.88M | -8.40M |
| Diluted EPS | - | - | -3.30 | -3.55 | -3.17 | -0.39 | -0.40 | -0.37 | -0.35 | -0.34 | -0.34 | -0.23 | -0.25 | -0.25 | -0.24 | -0.20 | -0.16 | -0.16 | -0.16 | -0.17 |
| R&D Expense | - | 1.75M | 1.89M | 2.40M | 2.82M | 2.72M | 3.32M | 3.26M | 4.18M | 4.10M | 3.69M | 3.54M | 3.68M | 4.41M | 3.50M | 3.33M | 3.34M | 3.28M | - | 3.03M |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|
| Revenue | 25.00K | - | 268.00K | 306.00K | 77.00K | 81.00K |
| Cost of Revenue | - | - | 193.00K | 210.00K | 82.00K | 164.00K |
| Gross Profit | - | - | 75.00K | 96.00K | -5.00K | -83.00K |
| Operating Expenses | - | - | 45.73M | 39.92M | 36.63M | 36.42M |
| Operating Income | -17.97M | - | -45.65M | -39.82M | -36.63M | -36.50M |
| EBITDA | - | - | -43.37M | -35.29M | -32.04M | -30.98M |
| Interest Expense | - | - | 61.00K | 55.00K | 28.00K | 9.00K |
| Pretax Income | - | - | -44.19M | -36.24M | -32.90M | -31.93M |
| Tax Provision | - | - | - | - | - | - |
| Net Income | -19.85M | - | -44.19M | -36.24M | -32.90M | -31.93M |
| Diluted EPS | -12.76 | - | -1.43 | -1.16 | -0.99 | -0.67 |
| R&D Expense | 7.78M | 11.02M | 14.24M | 15.22M | 14.73M | 13.17M |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|
| Total Assets | - | 14.80M | - | 116.33M | 95.44M | 72.58M | 101.93M |
| Current Assets | - | - | - | 90.12M | 61.34M | 47.60M | 40.77M |
| Cash & Equivalents | - | 13.53M | - | 29.88M | 3.88M | 4.04M | 3.94M |
| Inventory | - | - | - | - | - | - | - |
| Receivables | - | - | - | 113.00K | 160.00K | 34.00K | 12.00K |
| Total Liabilities | - | 12.33M | - | 17.39M | 25.28M | 24.77M | 26.52M |
| Current Liabilities | - | 11.24M | - | 15.54M | 24.44M | 24.77M | 24.19M |
| Long Term Debt | - | - | - | - | - | - | - |
| Total Debt | - | - | - | 2.83M | 1.86M | 840.00K | 2.34M |
| Total Equity | -106.62M | -125.57M | - | 98.94M | 70.16M | 47.80M | 75.41M |
| Shares Outstanding | - | - | - | 31.02M | 31.70M | 34.17M | 38.94M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | -16.87M | - | -34.61M | -27.19M | -14.19M | -25.62M |
| Investing Cash Flow | -149.00K | - | 5.55M | 438.00K | 11.74M | -28.50M |
| Financing Cash Flow | 9.16M | - | 5.00K | 752.00K | 2.61M | 54.03M |
| Capital Expenditure | -149.00K | - | -791.00K | -128.00K | -1.10M | -726.00K |
| Free Cash Flow | -17.02M | - | -35.40M | -27.32M | -15.29M | -26.35M |
| Net Change in Cash | - | - | -29.05M | -26.00M | 163.00K | -99.00K |
Ratios (Annual)
Figures in %.
| Metric | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|
| Gross Margin % | - | - | 28.0% | 31.4% | -6.5% | -102.5% |
| Operating Margin % | -71,884.0% | - | -17,034.3% | -13,013.4% | -47,577.9% | -45,066.7% |
| Net Margin % | -79,392.0% | - | -16,487.3% | -11,843.8% | -42,724.7% | -39,417.3% |
| ROE % | 15.8% | - | -44.7% | -51.7% | -68.8% | -42.3% |
| ROCE % | -505.7% | - | -45.3% | -56.1% | -76.6% | -47.0% |
Shareholding Pattern
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | Baker Bros. Advisors, LP | 14.29% | 5.50M | $11.46M |
| 2 | Whetstone Capital Advisors, LLC | 8.59% | 3.31M | $6.89M |
| 3 | Aberdeen Group plc | 7.16% | 2.75M | $5.74M |
| 4 | Vivo Capital, LLC | 4.29% | 1.65M | $3.44M |
| 5 | Vanguard Capital Management LLC | 3.37% | 1.30M | $2.71M |
| 6 | CAPTRUST Financial Advisors | 1.39% | 535.75K | $1.12M |
| 7 | Geode Capital Management, LLC | 0.91% | 348.97K | $727.60K |
| 8 | Blackrock Inc. | 0.58% | 221.37K | $461.55K |
| 9 | AWM Investment Company, Inc. | 0.54% | 207.38K | $432.39K |
| 10 | Vanguard Fiduciary Trust Co | 0.44% | 170.91K | $356.34K |
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for SERA
1 in 10 U.S. Babies Are Born Too Early. A Leading OB-GYN Says Most Mothers Can Learn Their Risk by Week 21, and Do Something About It.
Preterm birth affects about 1 in 10 U.S. pregnancies. It's one of the most common pregnancy complications. It's also one nobody warns you about. Yet most expecting mothers never learn their own risk until something goes wrong, because docto…
Sera (SERA) Q2 2026 Earnings Call Transcript
Illinois Medicaid coverage for PreTRM test unlocks 50,000 annual births as payer access expands.
SERA PROGNOSTICS APPOINTS SCOTT GLEASON CHIEF FINANCIAL OFFICER
Sera Prognostics Inc., The Pregnancy Company® (Nasdaq: SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomarker information to doctors and patients, announced today that Scott Gleason has been app…
Sera Prognostics Inc (SERA) (Q2 2026) Earnings Call Highlights: Payer Momentum Builds with ...
Despite minimal revenue, Sera Prognostics advances commercial strategy with new payer programs and a strengthened cash runway through 2029.
Sera Prognostics Q2 Earnings Call Highlights
Sera Prognostics (NASDAQ:SERA) reported modest second-quarter revenue while outlining progress in payer engagement, Illinois Medicaid policy, clinical evidence and European regulatory preparations for its PreTRM Test-guided care platform. R…
Sera Prognostics, Inc. (SERA) Reports Q2 Loss, Misses Revenue Estimates
Sera Prognostics (SERA) delivered earnings and revenue surprises of -28.57% and -76.92%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?
SERA — Frequently Asked Questions
What is the current share price of Sera Prognostics, Inc. (SERA)?
As of 2026-09-19 21:16 PDT, Sera Prognostics, Inc. (SERA) trades at $2.01 on NasdaqGM. Its 52-week range is $1.59 to $3.75.
What is the market capitalisation of SERA?
Sera Prognostics, Inc. (SERA) has a market capitalisation of $77.35M on NasdaqGM.
What is the P/E ratio of SERA?
SERA trades at a trailing price-to-earnings (P/E) ratio of -3.05. The industry average P/E is 24.83. Its price-to-book (P/B) ratio is 1.38.
What is the return on equity (ROE) of SERA?
SERA has a return on equity (ROE) of -45.03%. Its return on capital employed (ROCE) is -46.95%.
Is SERA a good stock to buy?
This page provides a data-driven analysis of Sera Prognostics, Inc. (SERA), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.